Glad we are all on the same page.
    Cost/copay is another to consider. The more competition, the better the prices. So hopefully more on the market means more patients are able to afford what can be astronomical copays in some cases.

    I will say, however, my experience with the investigational BRAF/MEKi (encorafenib + binimetinib) has been quite positive. My understanding is this combo has not seen the pyrexia as the others are. IF indeed true, this would be a notable & important difference and may very much sway usage.

    Latest Activity